Medical adherence in hypertensive patients treated by triple fixed-dose combination of amlodipine / indapamide / perindopril arginine (results of the Study DOKAZATEL’STVO)

Objective. To estimate changes in medication adherence in patients treated with fixed-dose combination of amlodipine / indapamide / perindopril arginine included in DOKAZATEL’STVO observational study.

Design and methods. Effects of the fixed-dose combination of amlodipine / indapamide / perindopril arginine on medication adherence were assessed in 1554 patients who filled in the questionnaire at baseline and at the last visit. Primary outcomes of the study included the change in the office and ambulatory (home blood pressure (BP) monitoring) systolic and diastolic BP from baseline to 3 months and rate of the achievement of target BP < 140/90 mmHg after 3-month treatment. Adherence was assessed by special questionnaire.

Results. The fixed-dose combination of amlodipine / indapamide / perindopril arginine resulted in the decrease in systolic BP by 39.5 mmHg and diastolic BP by 18.8 mmHg after 3 months. Target office BP < 140/90 mmHg was achieved in 87 %. High adherence at baseline was observed in 7,1 % patients, after 3 months of treatment — in 38,3 % (p < 0,001). Mean adherence score increased from 2,9 ± 1,6 to 5,0 ± 1,1 (p < 0,001). Study drug intake was associated with increase in motivation and awareness from 38 % to 95,4 % and from 19,8 % to 67,3 %, respectively (p < 0,001 for trend).

Conclusions. The administration of the fixed-dose combination of amlodipine / indapamide / perindopril arginine was associated with well tolerated BP decrease and significant increase in medication adherence and motivation even in the absence of specific targeted interventions.

1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Bumier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953— 2041. doi:10.1097/HJH.0000000000001940

2. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819-824. doi:10.1097/HJH.0b013e3282f4edd7

3. Gale NK, Greenfield S, Gill P, Gutridge K, Marshall T. Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. BMC Fam Pract. 2011;12:59. doi:10.1186/1471-2296-12-59

4. Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS, Morisky DE et al. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58(5):804—810. doi:10.1161/HYPERTENSIONAHA.111.176859

5. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-1605. doi:10.1161/CIRCULATIONAHA.108.830299

6. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich). 2008;10 (1Suppl1):20-26.

7. van Kleef ME, Spiering W. Hypertension: overly important but under-controlled. Eur J Prev Cardiol. 2017;24(3suppl):36-43. doi:10.1177/2047487317709116

8. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218-225. doi:10.1161/HYPERTENSIONAHA.113.00687

9. Corrao G, ParodiA, Nicotra F, ZambonA, Merlino L, Cesana G et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011 ;29(3):610—618. doi:10.1097/HJH.0b013e328342ca97

10. Boytsov SA, Balanova YA, Shalnova SA, Deev AD,Artamonov GV, Gatagonov TM et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. by the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14. In Russian.

11. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagava-thula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4): e5641. doi:10.1097/MD.0000000000005641

12. Whelton PK, Carey RM,AronowWS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066

13. Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). Am J Cardiol. 2007;100(2):159-163. doi:10.1016/j.amjcard.2007.02.073

14. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G et al. ACE inhibition with perindopril andendothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237-246. doi:10.1016/j.cardiores.2006.10.021

15. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503-1510

16. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet. 2005;366 (9489):895-906. doi:10.1016/S0140-6736(05)67185-1

17. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48(3):374-384. doi:10.1161/01.HYP.0000231662.77359.de

18. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041. doi:10.1016/S0140-6736(01)06178-5

19. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21 (12):2409-2417. doi:10.1097/01.hjh.0000084782.15238.a2

20. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63(2):259-264. doi:10.1161/HYPERTENSIONAHA.113.02252

21. T oth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-145. doi:10.1007/s40256-014-0067-2

22. Pall D, Szanto I, Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014;34(10):701-708. doi:10.1007/s40261-014-0223-0

23. Abraham G, Dezsi C. The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide and amlodipine: the Results of the PETRA Study. Adv Ther. 2017;34(7):1753-1763. doi:10.1007/s12325-017-0572-1

24. Lutay MI, on behalf of the TRIUMF multicenter study group. Efficiency of the combined treatment of arterial hypertension in Ukraine: results of the TRIUMF multicenter study. 2016;4:17-28. In Ukranian.

25. Kobalava ZD, Troitskaya EA, Tolkacheva VV. Combined therapy of arterial hypertension with a triple fixed-dose combination of amlodipine/indapamide/perindopril arginine in real clinical practice: the organization and the main results of the DOKAZATEL’STVO (Proof) Study. Kardiologiia. 2018;58(9):21-30. https://doi.org/10.18087/cardio.2018.9.10170. In Russian.

26. Girerd X, Radauceanu A, Achard JM, Fourcade J, Tournier B, Brillet G et al. Evaluation of patient compliance among hypertensive patients treated by specialists. Arch Mal Coeur Vaiss. 2001;94(8): 839-842.

27. Kotovskaya YuV, Villevalde SV, Tigai ZhG, Kobalava ZhD. Hypertensive patients’ adherence, motivation, and awareness during fixed-dose perindopril A and amlodipine combination treatment (Results of the CONSTANTArial). Ter Arkh. 2015;87(2):64-69. In Russian. https://doi.org/10.17116/terarkh201587264-69

28. McCallum L. Hypertension — state of the art 2017. Clin Med (Lond). 2017;17(4):338-340. doi:10.7861/clinmedicine.17-4-338

29. Marquez PHP, Torres OH, San-Jose A, Vidal X, Agusti A, Formiga F et al. Potentially inappropriate antihypertensive prescriptions to elderly patients: results of a prospective, observational study. Drugs Aging. 2017;34(6):453-466. doi:10.1007/s40266-017-0452-z

30. Petrak O, Zelinka T, Strauch B, Rosa J, Somloova Z, Indra T et al. Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. J Hum Hypertens. 2016;30(1):35—39. doi:10.1038/jhh.2015.24

31. Al-Ganmi AH, Perry L, Gholizadeh L, Alotaibi AM. Cardiovascular medication adherence among patients with cardiac disease: a systematic review. J Adv Nurs. 2016;72(12):3001-3014.doi:10.im/jan.13062

32. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26(9):2065-2076. doi:10.1185/03007995.2010.494462

33. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a metaanalysis. Am J Med. 2007;120(8):713-719. doi:10.1016/j.amjmed.2006.08.033

34. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ. 2012;15(5):897-905. doi:10.3111/13696998.2012.689792

35. Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and adherence to treatment with perindopril / indapamide / amlodipine single-pill combination in a Greek Population with hypertension. Clin Drug Investig. 2019;39(4):385-393. doi:10.1007/s40261-019-00761-0